Q-omics provides the consensus-scored MIR578 profile across patient tissues and cancer cell-line models. MIR578 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MIR578 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, MIR578 RNA expression shows 9,641 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUSC, LUAD, and THYM as cancer lineages where MIR578 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR578 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR578 survival associations across molecular data types. MIR578 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR578 RNA expression–survival associations across cancer types. High MIR578 expression shows unfavorable associations in LUSC, STAD, READ and ACC, but favorable associations in UCS and OV. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify LUSC as the clearest survival context for MIR578 RNA expression.
This table summarizes MIR578 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR578. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR578 shows lower tumor expression in THCA and KICH and higher tumor expression in LUAD. The LUAD box plot shows higher MIR578 RNA expression in tumor versus normal tissue (log2 FC = +0.219, t-test p = .039).
This table shows molecular features associated with MIR578 in patient tissues and cancer cell lines. In patient samples, MIR578 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
